Array BioPharma Inc. (ARRY)

16.98
NASDAQ : Health Technology
Prev Close 17.08
Day Low/High 16.89 / 17.37
52 Wk Low/High 7.15 / 20.21
Avg Volume 2.56M
Exchange NASDAQ
Shares Outstanding 210.64M
Market Cap 3.60B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
Interesting ARRY Put And Call For March 2014

Interesting ARRY Put And Call For March 2014

Investors in Array BioPharma Inc. saw new options become available this week, for the March 2014 expiration.

Array Seeks Asthma Drug Partner Following Mid-Stage Study Results

Array Seeks Asthma Drug Partner Following Mid-Stage Study Results

Array's ARRY-502 represents a new way of treating asthma.

TSRX, CYTK, ARRY: 3 Stocks on TV

TSRX, CYTK, ARRY: 3 Stocks on TV

StockMarketMentor.com founder Dan Fitzpatrick details how to play three stocks Jim Cramer discussed on CNBC's "Mad Money" last night.

Cramer's 'Mad Money' Recap: Ignore the Headlines

Cramer's 'Mad Money' Recap: Ignore the Headlines

The stock market is doing better than investors think, Cramer asserts.

ASCO '13: Array Drug First to be Effective Against Melanoma of the Eye

ASCO '13: Array Drug First to be Effective Against Melanoma of the Eye

Melanoma of the eye is rare but hard to treat.

10 ASCO '13 Abstracts You Can Read Right Now

10 ASCO '13 Abstracts You Can Read Right Now

Get a head start on searching through ASCO abstracts with these 10 summaries.

4 Health Care Stocks Under $10 to Watch

4 Health Care Stocks Under $10 to Watch

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

10 Biotech Stocks With A History Of Beating Earning Expectations

10 Biotech Stocks With A History Of Beating Earning Expectations

The fourth quarter earnings season has just begun. Some companies manage to consistently surprise the market with positive earnings reports. [...]

The Twitterverse's Biotech Stock Picks for 2013

The Twitterverse's Biotech Stock Picks for 2013

TheStreet's readers took to Twitter to offer their biotech stock predictions for 2013.

4 Biotech Stocks Under $10 Moving Higher

4 Biotech Stocks Under $10 Moving Higher

If you time your trade correctly, combining technical indicators with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

Stocks Finish Tough Week With Slight Gains

Stocks Finish Tough Week With Slight Gains

All three major equity averages still lose more than 2% for the week after the steep post-election selling.

4 Biotech Stocks Under $10 Soaring Higher

4 Biotech Stocks Under $10 Soaring Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Stocks Under $10: Blossoming Biotech Play

Stocks Under $10: Blossoming Biotech Play

Portfolio manager David Peltier discusses a hot biotech stock with a promising clinical pipeline.

3 Stocks Under $10 Moving Higher

3 Stocks Under $10 Moving Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Array BioPharma To Present At The UBS Global Life Sciences Conference

Array BioPharma To Present At The UBS Global Life Sciences Conference

Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the UBS Global Life Sciences Conference in New York City.

Array BioPharma's CEO Presents At Morgan Stanley Healthcare Conference - Transcript

Array BioPharma's CEO Presents At Morgan Stanley Healthcare Conference - Transcript

Array BioPharma's CEO Presents at Morgan Stanley Healthcare Conference - Transcript

Array BioPharma Announces Changes To Board Of Directors

Array BioPharma Announces Changes To Board Of Directors

Array BioPharma Inc. (NASDAQ: ARRY) announced that Francis Bullock, Ph.

Array BioPharma To Present At The Stifel Nicolaus Healthcare, NewsMakers In The Biotech Industry And Morgan Stanley Global Healthcare Conferences

Array BioPharma To Present At The Stifel Nicolaus Healthcare, NewsMakers In The Biotech Industry And Morgan Stanley Global Healthcare Conferences

Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the following upcoming conferences.

Array BioPharma's CEO Discusses F4Q2012 Results - Earnings Call Transcript

Array BioPharma's CEO Discusses F4Q2012 Results - Earnings Call Transcript

Array BioPharma's CEO Discusses F4Q2012 Results - Earnings Call Transcript

Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2012

Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2012

Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the fourth quarter and full year of fiscal 2012.

Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2012 On August 13, 2012

Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2012 On August 13, 2012

Array BioPharma Inc. (Nasdaq:ARRY) will report financial results for the fourth quarter and full year of fiscal 2012 on Monday, August 13, 2012, and will hold a conference call on Tuesday, August 14, 2012 at 9:00 a.

Array BioPharma’s ARRY-797 Meets Primary Endpoint In Clinical Proof Of Concept Trial In Osteoarthritis Patients Whose Pain Is Poorly Controlled By NSAIDs

Array BioPharma’s ARRY-797 Meets Primary Endpoint In Clinical Proof Of Concept Trial In Osteoarthritis Patients Whose Pain Is Poorly Controlled By NSAIDs

Array BioPharma (NASDAQ: ARRY) today announced that ARRY-797 met its primary endpoint in a randomized, placebo-controlled and active-controlled (oxycodone ER) Phase 2 clinical trial in 157 osteoarthritis patients...

Andrew Robbins, Senior Vice President, Commercial Operations, Array BioPharma (Photo: Business Wire)

Andrew Robbins, Senior Vice President, Commercial Operations, Array BioPharma (Photo: Business Wire)

Array BioPharma (NASDAQ: ARRY) announced today that it has appointed Andrew Robbins to the position of Senior Vice President of Commercial Operations.

8 Stocks Under $10 Skyrocketing Higher

8 Stocks Under $10 Skyrocketing Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Array BioPharma Achieves $8.5 Million Clinical Milestone In Amgen Diabetes Collaboration

Array BioPharma Achieves $8.5 Million Clinical Milestone In Amgen Diabetes Collaboration

Array BioPharma Inc. (NASDAQ: ARRY) announced today that an $8.

Clovis Oncology And Array BioPharma Announce Agreement To Discover Novel Mutant KIT Inhibitor

Clovis Oncology And Array BioPharma Announce Agreement To Discover Novel Mutant KIT Inhibitor

Clovis Oncology, Inc. (Nasdaq: CLVS) and Array BioPharma (Nasdaq: ARRY) announced today an agreement for the discovery of a novel KIT inhibitor targeting resistance mutations for the treatment of GIST.

Array BioPharma To Present At The JMP Securities Healthcare Conference 2012

Array BioPharma To Present At The JMP Securities Healthcare Conference 2012

Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the JMP Securities Healthcare Conference 2012 in New York City.

Synta: Waiting, Waiting, Waiting for Lung Cancer Data

Synta: Waiting, Waiting, Waiting for Lung Cancer Data

Synta is taking its sweet time releasing highly anticipated results from a phase II lung cancer trial.

Promising Data For KRAS Mutant Advanced NSCLC Patients Presented At ASCO

Promising Data For KRAS Mutant Advanced NSCLC Patients Presented At ASCO

Promising data from a double-blind, randomized Phase 2 study conducted by AstraZeneca comparing the efficacy of selumetinib (AZD6244/ARRY-886) in combination with docetaxel versus docetaxel alone in 87 second-line ...

MEK162 Shows Promising Clinical Activity In Ongoing Phase 2 Trial

MEK162 Shows Promising Clinical Activity In Ongoing Phase 2 Trial

Promising data on MEK162 in an ongoing Phase 2 trial of patients with BRAF and NRAS mutated advanced melanoma was presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

TheStreet Quant Rating: D (Sell)